(Q46248271)

English

Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis

scientific article published on 3 November 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/22052885

Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis (English)

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/22052885

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

5-fluorocytosine

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Linda-Gail Bekker

10

object named as

Linda-Gail Bekker

1 reference

Europe PubMed Central

20 December 2017

Joseph N. Jarvis

object named as

Joseph N Jarvis

4

0 references

Graeme Meintjes

object named as

Graeme Meintjes

3

0 references

11

object named as

Robin Wood

1 reference

Europe PubMed Central

20 December 2017

Thomas Harrison

object named as

Thomas S Harrison

12

0 references

object named as

Shabbar Jaffar

9

0 references

1

object named as

Angela Loyse

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/22052885

7

object named as

Kevin Rebe

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/22052885

author name string

Douglas Wilson

2

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/22052885

Tihana Bicanic

5

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/22052885

Leesa Bishop

6

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/22052885

Anthony Williams

8

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/22052885

language of work or name

0 references

publication date

3 November 2011

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/22052885

Clinical Infectious Diseases

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/22052885

54

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/22052885

1

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/22052885

121-128

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/22052885

Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

Impact of HIV infection on meningitis in Harare, Zimbabwe: a prospective study of 406 predominantly adult patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

Meningitis in a community with a high prevalence of tuberculosis and HIV infection

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

Causes of death in a rural, population-based human immunodeficiency virus type 1 (HIV-1) natural history cohort in Uganda.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

Successful public/private donation programs: a review of the Diflucan Partnership Program in South Africa

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

Effects of voriconazole on Cryptococcus neoformans

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection. The California Collaborative Treatment Group

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

Efficacy of voriconazole in a murine model of cryptococcal central nervous system infection.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

Voriconazole proves effective in long-term treatment of a cerebral cryptococcoma in a chronic nephropathic HIV-negative patient, after fluconazole failure

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

Voriconazole use and pharmacokinetics in combination with interferon-gamma for refractory cryptococcal meningitis in a patient receiving low-dose ritonavir

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

Long-term efficacy and safety of TDM-assisted combination of voriconazole plus efavirenz in an AIDS patient with cryptococcosis and liver cirrhosis.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

Complexity of interactions between voriconazole and antiretroviral agents

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

Fungal Burden, Early Fungicidal Activity, and Outcome in Cryptococcal Meningitis in Antiretroviral-Naive or Antiretroviral-Experienced Patients Treated with Amphotericin B or Fluconazole

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR745

21 January 2018

Identifiers

10.1093/CID/CIR745

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/22052885

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/22052885

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46248271&oldid=2102132648"